Journal Home > Just Accepted

Mesenchymal stem cells (MSCs) transplantation is a promising strategy for osteoporosis treatment. However, limited sources and poor tissue-homing efficiency limit their clinical capabilities. In this study, we isolated a kind of MSCs from women’s menstrual blood (MenSCs) noninvasively and established a novel MSCs bone marrow-targeted delivery system by utilizing water-in-oil-in-water droplet microfluidics. MenSCs were encapsulated within β-cyclodextrin-functionalized alginate microcapsules loaded with zoledronates, which has a high affinity for bone. With this delivery system, MenSCs could be preferentially delivered to the bone marrow tissues via intravenous infusion, and restored bone mass by remodeling the bone marrow niche in situ in ovariectomized mouse models. Moreover, scRNA-seq analysis demonstrated that those MenSCs homed to the bone marrow recruited CD4+FOXP3+ natural regulatory T (nTreg) cells by secreting CCL28. The recruited nTreg promoted CD8+ T cells to secret WNT10B, activating the Wnt signaling in osteoblasts and thus promoting bone formation in situ in the bone marrow. This study reveals a promising application of MenSCs in postmenopausal osteoporosis treatment and highlights the clinical value of MenSCs by encouraging women to reserve autologous MenSCs before menopause to prevent and alleviate postmenopausal osteoporosis.

Video
Electronic Supplementary Material 2.avi
Electronic Supplementary Material 3.avi
Publication history
Copyright
Rights and permissions

Publication history

Received: 15 February 2024
Revised: 20 April 2024
Accepted: 22 April 2024
Available online: 23 April 2024

Copyright

© Tsinghua University Press 2024

Rights and permissions

Reprints and Permission requests may be sought directly from editorial office.
Email: nanores@tup.tsinghua.edu.cn

Return